Hepatitis B Virus | China In-Depth | China | 2020
Hepatitis B virus (HBV) infection is a major public health burden in China, and chronically infected HBV patients are at a high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority of hepatitis B virus patients in China are prescribed older, generic agents such as pegylated interferon-α-2a (Pegasys), pegylated interferon-α-2b (Peg-Intron), tenofovir disoproxil fumarate (Viread), and entecavir (Baraclude). However, we expect the recently launched tenofovir alafenamide (Gilead’s Vemlidy), in addition to several novel therapies set to launch for hepatitis B virus during the forecast period, to result in significant growth of the Chinese hepatitis B virus market. Moreover, we expect ongoing reforms in China’s regulatory and A&R landscape to encourage MNCs to enter the hepatitis B virus market.
- How large is China’s drug-treatable hepatitis B virus population, and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s hepatitis B virus market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the hepatitis B virus pipeline in China? What is their potential in terms of sales/uptake in hepatitis B virus? What are interviewed experts’ opinions on the key emerging therapies?
- What are the key drivers and constraints in the Chinese hepatitis B virus market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
RELEASE DATE
April 2020
GEOGRAPHY
China
PRIMARY RESEARCH
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with hepatologists and gastroenterologists. Supported by survey data collected for this and other DRG research.
EPIDEMIOLOGY
Total prevalence of hepatitis B virus in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales and patient shares of key hepatitis B virus agents through 2029, based on primary and secondary market research to formulate bottom-up assumptions
EMERGING THERAPIES
Phase III/PR: 4 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products
